| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ... Journal of hepatology 73 (1), 202-209, 2020 | 3913 | 2020 |
| A multisociety Delphi consensus statement on new fatty liver disease nomenclature ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, ... Hepatology 78 (6), 1966-1986, 2023 | 3150 | 2023 |
| MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease M Eslam, AJ Sanyal, J George, A Sanyal, B Neuschwander-Tetri, ... Gastroenterology 158 (7), 1999-2014. e1, 2020 | 3082 | 2020 |
| Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study MJ Armstrong, P Gaunt, GP Aithal, D Barton, D Hull, R Parker, ... The Lancet 387 (10019), 679-690, 2016 | 2163 | 2016 |
| A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis PN Newsome, K Buchholtz, K Cusi, M Linder, T Okanoue, V Ratziu, ... New England Journal of Medicine 384 (12), 1113-1124, 2021 | 1493 | 2021 |
| Resolving the fibrotic niche of human liver cirrhosis at single-cell level P Ramachandran, R Dobie, JR Wilson-Kanamori, EF Dora, ... Nature 575 (7783), 512-518, 2019 | 1300 | 2019 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1213 | 2019 |
| Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease PJ Eddowes, M Sasso, M Allison, E Tsochatzis, QM Anstee, D Sheridan, ... Gastroenterology 156 (6), 1717-1730, 2019 | 1213 | 2019 |
| Pathogenesis of non-alcoholic fatty liver disease JK Dowman, JW Tomlinson, PN Newsome QJM: An International Journal of Medicine 103 (2), 71-83, 2010 | 1090 | 2010 |
| Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis RS Taylor, RJ Taylor, S Bayliss, H Hagström, P Nasr, JM Schattenberg, ... Gastroenterology 158 (6), 1611-1625. e12, 2020 | 908 | 2020 |
| Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol … R Williams, R Aspinall, M Bellis, G Camps-Walsh, M Cramp, A Dhawan, ... The Lancet 384 (9958), 1953-1997, 2014 | 733 | 2014 |
| FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation … PN Newsome, M Sasso, JJ Deeks, A Paredes, J Boursier, WK Chan, ... The lancet Gastroenterology & hepatology 5 (4), 362-373, 2020 | 688 | 2020 |
| A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis SA Harrison, P Bedossa, CD Guy, JM Schattenberg, R Loomba, R Taub, ... New England Journal of Medicine 390 (6), 497-509, 2024 | 659 | 2024 |
| Advancing the global public health agenda for NAFLD: a consensus statement JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, ... Nature Reviews Gastroenterology & Hepatology 19 (1), 60-78, 2022 | 599 | 2022 |
| Guidelines on the management of abnormal liver blood tests PN Newsome, R Cramb, SM Davison, JF Dillon, M Foulerton, EM Godfrey, ... Gut 67 (1), 6-19, 2018 | 574 | 2018 |
| Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper T Boettler, PN Newsome, MU Mondelli, M Maticic, E Cordero, M Cornberg, ... JHEP reports 2 (3), 100113, 2020 | 554 | 2020 |
| Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling DC Hay, J Fletcher, C Payne, JD Terrace, RCJ Gallagher, J Snoeys, ... Proceedings of the National Academy of Sciences 105 (34), 12301-12306, 2008 | 533 | 2008 |
| Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells SFH de Witte, F Luk, JM Sierra Parraga, M Gargesha, A Merino, ... stem cells 36 (4), 602-615, 2018 | 509 | 2018 |
| Modulation of insulin resistance in nonalcoholic fatty liver disease RS Khan, F Bril, K Cusi, PN Newsome Hepatology 70 (2), 711-724, 2019 | 487 | 2019 |
| Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis MJ Armstrong, D Hull, K Guo, D Barton, JM Hazlehurst, LL Gathercole, ... Journal of hepatology 64 (2), 399-408, 2016 | 479 | 2016 |